News Releases

Released : November 09, 2018 07:00   RNS Number : 8499G MaxCyte, Inc. 09 November 2018                                                                                                       MaxCyte, Inc. ("MaxCyte")   CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement
Nov 09, 2018
Released : October 31, 2018 16:25   RNS Number : 9281F MaxCyte, Inc. 31 October 2018         MaxCyte, Inc. ("MaxCyte" or the "Company")   Result of AGM   Gaithersburg, MD - 31 October 2018 : MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that at its
Oct 31, 2018
Gaithersburg,  Maryland  –  October 30, 2018:  MaxCyte announced today that  Debra K. Bowes , Chief Business Officer, CARMA Cell Therapy, will present  “Novel mRNA-based Autologous CAR Therapies in Oncology”  at the 24th Annual International Partnering Conference BIO-EUROPE.
Oct 30, 2018
Released : October 10, 2018 07:00   RNS Number : 4884D MaxCyte, Inc. 10 October 2018         MaxCyte, Inc. ("MaxCyte" or the "Company")   MaxCyte Commences Dosing in First Clinical Trial in Solid Tumours   First patient dosed in Phase I clinical study to evaluate MaxCyte's lead CAR therapeutic in
Oct 10, 2018
Released : October 08, 2018 07:00   RNS Number : 2057D MaxCyte, Inc. 08 October 2018         MaxCyte, Inc. ("MaxCyte" or the "Company")   Notification of Annual General Meeting   Gaithersburg, MD - 08 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company
Oct 08, 2018
Released : September 24, 2018 07:00   RNS Number : 6299B MaxCyte, Inc. 24 September 2018         MaxCyte, Inc. ("MaxCyte" or the "Company")   Results for the Six Months ended 30 June 2018   Gaithersburg, Maryland - 24 September 2018 - MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and
Sep 24, 2018
Released : September 10, 2018 07:00   RNS Number : 2308A MaxCyte, Inc. 10 September 2018       MaxCyte, Inc. ("MaxCyte" or the "Company")   Grant of Options   Maryland, USA - 10 September 2018:   MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the
Sep 10, 2018
Released : September 03, 2018 07:00   RNS Number : 4933Z MaxCyte, Inc. 03 September 2018       MaxCyte, Inc. ("MaxCyte" or the "Company")   Notice of Half Year Results   Gaithersburg, MD - 03 September 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company , will
Sep 03, 2018
Released : July 26, 2018 17:33   RNS Number : 9375V MaxCyte, Inc. 26 July 2018         MaxCyte, Inc. ("MaxCyte" or the "Company")   Person Closely Associated Dealing   Maryland, USA , 26 July 2018 - MaxCyte (LSE: MXCT, MXCR)  the global cell-based medicines and technology company, announces that
Jul 26, 2018